As such, genetic and/or pharmacological inhibition of SIRT1 significantly reduced FZD7 levels through perturbing the binding of β-catenin and c-Jun transcription factors to the endogenous FZD7 promoter, reversing the potent tumourigenic effect of FZD7 overexpression in breast cancer cells [193]. This evidence concerns the gene FZD7 and breast cancer.